New injection study aims to ease uncontrollable eye blinking

NCT ID NCT07489430

Not yet recruiting Symptom relief Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a botulinum toxin called DaxibotulinumtoxinA (DAXI) for adults with blepharospasm, a condition causing uncontrollable blinking or eye muscle spasms. Twenty participants will receive up to three injection cycles over 12 months. The goal is to measure how long symptom relief lasts and track safety. This is an early-phase study, not a cure, but aims to improve daily life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLEPHAROSPASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign essential blepharospasm Dystonia parkinsonian disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLEPHAROSPASM BLEPHAROSPASM OF BOTH EYELIDS BLEPHAROSPASM OF LEFT EYELID BLEPHAROSPASM OF RIGHT EYELID BLEPHAROSPASM, BENIGN ESSENTIAL

Contacts and locations

Locations

Parkinson Disease and Movement Disorders Center at the University of Pennsylvania

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.